Noboru Hattori Selected Research

Chemoradiotherapy

12/2021	Potential benefits of volumetric modulated arc therapy to reduce the incidence of ≥ grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients.
9/2021	Pneumatosis Intestinalis following Radiation Esophagitis during Chemoradiotherapy for Lung Cancer: A Case Report.
1/2021	Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer.
1/2021	Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
10/2017	Chronic Intestinal Pseudo-obstruction and Orthostatic Hypotension Associated with Small Cell Lung Cancer that Improved with Tumor Reduction after Chemoradiotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Noboru Hattori Research Topics

Disease

40	Neoplasms (Cancer) 07/2022 - 04/2003
33	Lung Neoplasms (Lung Cancer) 07/2022 - 02/2007
28	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2022 - 07/2006
25	Interstitial Lung Diseases (Interstitial Lung Disease) 07/2022 - 01/2003
16	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2021 - 11/2002
15	Adenocarcinoma of Lung 01/2022 - 06/2007
15	Fibrosis (Cirrhosis) 01/2021 - 11/2002
13	Pneumonia (Pneumonitis) 10/2022 - 05/2008
12	Chronic Obstructive Pulmonary Disease (COPD) 07/2021 - 12/2008
11	Asthma (Bronchial Asthma) 12/2022 - 01/2009
11	Idiopathic Pulmonary Fibrosis 01/2021 - 01/2003
9	Disease Progression 07/2022 - 11/2016
9	Lung Injury 01/2022 - 11/2002
9	Inflammation (Inflammations) 01/2021 - 12/2008
9	Neoplasm Metastasis (Metastasis) 01/2021 - 02/2007
8	Adenoma (Adenomas) 01/2022 - 01/2018
6	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2021 - 10/2017
6	Adenocarcinoma 01/2019 - 05/2006
5	Carcinoma (Carcinomatosis) 10/2021 - 06/2011
5	Bronchiectasis 02/2021 - 01/2018
4	Adrenocortical Adenoma (Disease, Conn's) 01/2022 - 12/2018
4	Lewis Lung Carcinoma 09/2018 - 02/2007
3	Rheumatoid Arthritis 10/2022 - 09/2009
3	Acute Lung Injury 01/2022 - 01/2020
3	Radiation Pneumonitis 12/2021 - 03/2012
3	Glucose Intolerance 11/2021 - 01/2013
3	Emphysema 04/2021 - 01/2016
3	Organizing Pneumonia 11/2020 - 01/2009
3	Idiopathic Interstitial Pneumonias 04/2020 - 01/2003
3	Breast Neoplasms (Breast Cancer) 01/2019 - 05/2006
3	Hemorrhage 12/2018 - 12/2012
3	Infections 12/2018 - 07/2017
3	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 12/2017 - 11/2016
2	Pulmonary Alveolar Proteinosis 02/2022 - 03/2012
2	Respiratory Insufficiency (Respiratory Failure) 02/2022 - 01/2017
2	Dyspnea (Shortness of Breath) 01/2022 - 02/2021
2	Cushing Syndrome 12/2021 - 12/2018
2	Carcinogenesis 10/2021 - 10/2020

Drug/Important Bio-Agent (IBA)

20	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2011
14	Bleomycin (Blenoxane)FDA LinkGeneric 01/2021 - 11/2002
11	Plasminogen Activator Inhibitor 1IBA 01/2019 - 11/2002
11	Plasminogen Activators (Plasminogen Activator)IBA 01/2019 - 11/2002
10	Immune Checkpoint InhibitorsIBA 02/2022 - 12/2018
10	Pharmaceutical PreparationsIBA 02/2021 - 01/2009
9	LigandsIBA 07/2022 - 02/2011
9	ErbB Receptors (EGF Receptor)IBA 01/2022 - 06/2008
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2003
7	AldosteroneIBA 01/2022 - 01/2018
7	CytokinesIBA 01/2021 - 05/2008
6	EnzymesIBA 01/2022 - 01/2012
6	pembrolizumabIBA 01/2022 - 03/2019
6	Tyrosine Kinase InhibitorsIBA 09/2021 - 06/2008
6	AntigensIBA 04/2021 - 05/2006
6	Mucin-1 (CA 15-3 Antigen)IBA 01/2019 - 12/2005
5	Prednisolone (Predate)FDA LinkGeneric 12/2022 - 01/2018
5	Anti-Bacterial Agents (Antibiotics)IBA 07/2022 - 07/2017
5	osimertinibIBA 01/2022 - 01/2019
5	Carboplatin (JM8)FDA LinkGeneric 11/2021 - 10/2011
5	Cisplatin (Platino)FDA LinkGeneric 02/2021 - 01/2016
5	Small Interfering RNA (siRNA)IBA 01/2021 - 04/2010
5	AntibodiesIBA 12/2019 - 06/2007
5	CollagenIBA 12/2017 - 02/2007
5	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 01/2016 - 10/2007
4	Immunoglobulin G (IgG)IBA 12/2022 - 01/2012
4	NivolumabIBA 02/2021 - 01/2018
4	Interleukin-6 (Interleukin 6)IBA 01/2021 - 04/2009
4	Messenger RNA (mRNA)IBA 01/2021 - 01/2018
4	ImmunosorbentsIBA 12/2019 - 01/2012
4	Bevacizumab (Avastin)FDA Link 12/2018 - 01/2017
4	CD13 Antigens (Alanine Aminopeptidase)IBA 01/2018 - 04/2003
4	Peptides (Polypeptides)IBA 11/2017 - 01/2015
4	Monoclonal AntibodiesIBA 07/2015 - 05/2006
4	PlasminogenIBA 10/2012 - 11/2002
3	SteroidsIBA 12/2022 - 01/2018
3	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2022 - 12/2018
3	mepolizumabIBA 01/2022 - 07/2021
3	Receptor for Advanced Glycation End ProductsIBA 01/2022 - 01/2017
3	HMGB1 Protein (HMG1)IBA 12/2021 - 01/2020
3	Etoposide (VP 16)FDA LinkGeneric 11/2021 - 01/2018
3	B7-H1 AntigenIBA 10/2021 - 08/2019
3	Adrenal Cortex Hormones (Corticosteroids)IBA 07/2021 - 12/2008
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 10/2011
3	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 01/2019 - 03/2018
3	suplatast tosilateIBA 01/2019 - 01/2009
3	Docetaxel (Taxotere)FDA Link 12/2018 - 01/2011
3	Sirolimus (Rapamycin)FDA Link 12/2017 - 11/2016
3	Glycoproteins (Glycoprotein)IBA 12/2017 - 06/2007
3	SK-216IBA 01/2016 - 11/2013
2	Interleukin-13IBA 12/2022 - 01/2016
2	Methotrexate (Mexate)FDA LinkGeneric 10/2022 - 09/2009
2	Trimethoprim (Proloprim)FDA LinkGeneric 07/2022 - 01/2021
2	Sulfamethoxazole FDA LinkGeneric 07/2022 - 01/2021
2	atezolizumabIBA 11/2021 - 01/2021

Therapy/Procedure

26	Therapeutics 07/2022 - 04/2003
22	Drug Therapy (Chemotherapy) 07/2022 - 01/2011
6	Radiotherapy 12/2021 - 06/2017
5	Chemoradiotherapy 12/2021 - 10/2017
5	Traction 02/2021 - 01/2018
4	Aftercare (After-Treatment) 06/2020 - 04/2003
2	Oral Administration 10/2022 - 06/2017